Explore

Researchers Uncover Rapid Contraction Mechanism in Single-Celled Organism, Informing Artificial Muscle Development

Researchers Uncover Rapid Contraction Mechanism in Single-Celled Organism, Informing Artificial Muscle Development

Scientists have identified the unique mechanism enabling the single-celled organism, Spirostomum ambiguum, to contract its body by one-quarter of its original length in under five milliseconds. This speed is hundreds of times faster than a human blink and significantly quicker than human muscle contraction. The research, published in the Proceedings of the National Academy of Sciences, reveals that the organism utilizes calcium ions and a specialized fishnet-like protein network for this rapid movement. Unlike human muscles that rely on adenosine triphosphate (ATP) for energy, Spirostomum ambiguum's contraction is powered by calcium ions, acting more like an electrical current. This discovery was made possible through electron and immunofluorescence microscopy, which allowed researchers to observe the myonemes—fibrous structures made from calcium-binding proteins centrin and Sfi1—forming a web around the organism. When calcium ions are present, the Sfi1 protein shifts from stiff to flexible, causing the fi...

Melbourne Biotech PremieHealth Explores Marsupial Milk for Premature Baby Nutrition

Melbourne Biotech PremieHealth Explores Marsupial Milk for Premature Baby Nutrition

PremieHealth, a Melbourne-based biotech company, is researching the unique properties of marsupial milk to develop advanced nutritional solutions for premature babies. Founders Professor Kevin Nicholas and Associate Professor Julie Sharp discovered that marsupial milk changes its composition as joeys develop, delivering specific biological signals that guide organ development. Human premature babies, born before these signals are fully received in the womb, often face lifelong health issues. PremieHealth aims to decode these developmental secrets from marsupial milk to create fortifiers that can mimic these crucial signals. The company has built a proprietary database of 105 bioactive compounds from various marsupial species, tracking lactation across their cycles to understand how these bioactives relate to development. Their initial product will be a precision-fermented fortifier based on human breast milk proteins, with marsupial-inspired bioactives to follow.

Texas Lawmaker Advocates for Continued Investment in Biotechnology to Boost Economy and Healthcare

Texas Lawmaker Advocates for Continued Investment in Biotechnology to Boost Economy and Healthcare

Dr. Jen Muhtaler, an engineer, physician, and candidate for Texas House District 47, is advocating for Texas to prioritize biotechnology and life sciences as key economic and healthcare initiatives. She emphasizes that biotech is crucial for translating medical discoveries into real-world care, including new cancer treatments, therapies for rare diseases, and improved diagnostics. Muhtaler highlights that Texas already possesses a strong foundation for leadership in this sector, citing institutions like MD Anderson and the Texas Medical Center, as well as growing innovation hubs such as Pegasus Park. She points to local companies like Lumos, Savara, and Vigilant as examples of the talent and entrepreneurial spirit driving the state's life sciences future. Muhtaler believes that elected officials should prioritize investment in biotech due as it provides direct returns for Texas families, offering greater access to clinical trials and emerging treatments, strengthening the healthcare workforce, attracting p...

Cellular Intelligence Appoints Moderna Co-founder Robert Langer and AI Pioneer Yann LeCun to Board, Advancing AI in Medicine

Cellular Intelligence Appoints Moderna Co-founder Robert Langer and AI Pioneer Yann LeCun to Board, Advancing AI in Medicine

Cellular Intelligence Appoints Moderna Co-founder Robert Langer and AI Pioneer Yann LeCun to Board, Advancing AI in Medicine

Pat Shirley Ryan Family Fund Awards Over $2.1 Million to Northwestern Biomedical Research

Pat Shirley Ryan Family Fund Awards Over $2.1 Million to Northwestern Biomedical Research

Northwestern University has distributed over $2.1 million through the Pat & Shirley Ryan Family Research Acceleration Fund to support eight biomedical research projects. This funding is part of a larger $35 million commitment from the Patrick George Ryan and Shirley Welsh Ryan Family aimed at high-impact research. The recent awards represent the fifth round of funding, bringing the total support from the fund to more than $10.9 million across 41 projects. The initiative is designed to provide crucial support for promising ideas at a transitional stage between academic discovery and practical application, a phase where additional validation and development are often required. Christopher de Clinton Conway, Chief Philanthropy, Communications & Strategic Partnerships Officer at Indiana Biosciences Research Institute (IBRI), highlighted this development on LinkedIn, emphasizing the fund's role in advancing biomedical discoveries.

IISc Scientists Control Human Cell Division with Blue Light, Bypassing Natural Scaffolding

IISc Scientists Control Human Cell Division with Blue Light, Bypassing Natural Scaffolding

Researchers at the Indian Institute of Science (IISc) in Bengaluru have developed a method to control human cell division using flashes of blue light. This technique, named Light-Induced Spindle Assembly (LISA), allows scientists to trigger the assembly of the microscopic machinery required for cell division by clustering Aurora A proteins. This is achieved by engineering human cells to attach Aurora A proteins to a light-sensitive module. When blue light is applied, these proteins rapidly clump together, activating them and initiating the formation of the mitotic spindle, which is crucial for DNA division. This breakthrough demonstrates that the massive Cep192 scaffold, previously thought necessary for Aurora A activation, is not essential. The LISA system can even rescue cells from division failure when their centrosomes, the natural organizers of microtubule threads, are intentionally destroyed. Unlike previous methods, LISA operates directly within living human cells and is fully reversible, allowing f...

UC San Diego Researchers Develop AI-Powered Virtual Cells to Accelerate Drug Discovery

UC San Diego Researchers Develop AI-Powered Virtual Cells to Accelerate Drug Discovery

Researchers at UC San Diego have developed an advanced imaging technique to create high-fidelity 4D movies of human cells, leading to the creation of virtual cells and an AI model named MitoSpace. This technology allows scientists to predict how mitochondria within human cells will respond to drug treatments. The team created a physics-based 'digital twin' of a real cancer cell, mapping the positions of mitochondria and their microtubule tracks, and incorporating motor proteins and laws of motion. This virtual cell's parameters were adjusted to match the behavior of real cells. Additionally, they trained MitoSpace using 40,000 single-cell 4D movies from cancer cells treated with 25 different compounds. Unlike traditional AI models, MitoSpace independently identified patterns in mitochondrial behavior, enabling it to group cells with similar responses and predict their energetic states based solely on mitochondrial shape and movement across various drug conditions. This approach achieved 75% accuracy in dis...

Georgia Tech Researchers Develop Biodegradable 'STAR Particles' to Enhance Skin Drug Delivery

Georgia Tech Researchers Develop Biodegradable 'STAR Particles' to Enhance Skin Drug Delivery

Researchers at Georgia Tech have developed biodegradable 'STAR particles' designed to improve the delivery of drugs directly to the skin. These microscopic particles feature tiny needles that painlessly puncture the skin's outer layer, the stratum corneum, which typically acts as a barrier to topical medications. This innovation aims to overcome the limitation of many dermatological drugs that are currently administered orally or via injection, leading to potential systemic side effects and reduced efficacy. The team has created STAR particles from three polymers: water-soluble poly(vinyl alcohol) (PVA), enzyme-degradable cellulose acetate (CA), and hydrolyzable polylactic acid (PLA). These biodegradable materials address environmental concerns associated with previous ceramic versions of the particles. The polymer STAR particles have demonstrated consistent skin-puncturing ability and remained intact after use, even after storage. This technology allows for the targeted delivery of medication directly to ...

Stratified Medicine Advances with AI and Genomic Technologies for Personalized Treatment

Stratified Medicine Advances with AI and Genomic Technologies for Personalized Treatment

Stratified medicine, also known as precision medicine, is evolving rapidly through the integration of artificial intelligence (AI) and genomic technologies. This approach focuses on customizing medical treatment for individual patients by utilizing biomarkers to identify specific subgroups within a diagnosis. The advancements allow for more targeted and effective therapies. AI and genomic technologies are enhancing the analysis of complex multimodal data, which includes imaging, physiological signals, and electronic health records. This comprehensive data analysis supports earlier diagnosis, more refined phenotyping, and improved risk stratification across various medical conditions. High-throughput pluripotent stem cell models combined with AI modeling are accelerating the development of precision medicine, particularly in fields such as oncology, neurodevelopmental and neurodegenerative disorders, and metabolic diseases. This shift moves away from a one-size-fits-all medical approach towards treatments t...

Scientists Identify Cortical Cells Capable of Initiating Sleep, Challenging Traditional Brain Sleep Theories

Scientists Identify Cortical Cells Capable of Initiating Sleep, Challenging Traditional Brain Sleep Theories

New research published in Nature by neuroscientists Geoffrey Terral and Renata Batista-Brito at the Albert Einstein College of Medicine in New York has identified a specific population of cortical cells capable of initiating sleep. These cells, known as Sst-Chodl neurons, constitute approximately one percent of the cortex's inhibitory neurons. Traditionally, sleep research has posited that the cerebral cortex passively responds to sleep signals originating from deeper brain regions. However, the study demonstrates that activating these Sst-Chodl neurons in mice is sufficient to induce sleep. This finding suggests that the cortex can not only perceive sleep rhythms but also actively initiate them, challenging the long-held assumption that subcortical regions are solely responsible for controlling sleep onset.

MaaT Pharma Shifts Focus to U.S. Clinical Trial for MaaT013 Following Negative European Regulatory Opinion

MaaT Pharma Shifts Focus to U.S. Clinical Trial for MaaT013 Following Negative European Regulatory Opinion

MaaT Pharma, a clinical-stage biotechnology company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) maintained its negative opinion regarding the Conditional Marketing Authorization (CMA) application for MaaT013 (Xervyteg®). This decision, following a re-examination, concerns the treatment of acute Graft-versus-Host Disease (aGvHD) in adult patients with gastrointestinal involvement refractory to prior lines of therapy. The CHMP's view is that the available clinical data, based on a single-arm trial, does not sufficiently characterize the benefit-risk profile of MaaT013. Consequently, MaaT Pharma will now prioritize advancing its U.S. development plan for MaaT013, focusing on a randomized controlled Phase 3 trial named PHOENIX. Feedback from a Type C interaction with the Food and Drug Administration (FDA) supports the advancement of PHOENIX as a registrational Phase 3 trial, with potential first patient enrollment in the first half of 2027, c...

Tumors Evade T-Cell Recognition by Hiding p53 Neoantigens, Dana-Farber Research Reveals

Tumors Evade T-Cell Recognition by Hiding p53 Neoantigens, Dana-Farber Research Reveals

New research led by the Dana-Farber Cancer Institute and Harvard Medical School has uncovered a mechanism by which tumors can evade detection by the immune system, specifically T-cells. The study, published in Immunity, found that despite the prevalence of TP53 mutations in cancer, which are attractive targets for personalized immunotherapies, tumors can actively restrict the presentation of p53-derived neoantigens on their surface. This means that even if a tumor has a mutation predicted to produce a strong neoantigen, the resulting peptide may not be processed, loaded onto a human leukocyte antigen (HLA) molecule, or displayed at sufficient levels on the tumor surface for T-cells to recognize it. The researchers utilized an ultrasensitive mass spectrometry-based immunopeptidomics platform, combined with tumor genomics, structural biology, and engineered T-cells, to directly investigate p53 peptide presentation.